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ABSTRACT
Background
Artemisinin derivatives used in recently introduced combination therapies (ACTs) for
Plasmodium falciparum malaria significantly lower patient infectiousness and have the potential
to reduce population-level transmission of the parasite. With the increased interest in malaria
elimination, understanding the impact on transmission of ACT and other antimalarial drugs
with different pharmacodynamics becomes a key issue. This study estimates the reduction in
transmission that may be achieved by introducing different types of treatment for symptomatic
P. falciparum malaria in endemic areas.
Methods and Findings
We developed a mathematical model to predict the potential impact on transmission
outcomes of introducing ACT as first-line treatment for uncomplicated malaria in six areas of
varying transmission intensity in Tanzania. We also estimated the impact that could be
achieved by antimalarials with different efficacy, prophylactic time, and gametocytocidal
effects. Rates of treatment, asymptomatic infection, and symptomatic infection in the six study
areas were estimated using the model together with data from a cross-sectional survey of 5,667
individuals conducted prior to policy change from sulfadoxine-pyrimethamine to ACT. The
effects of ACT and other drug types on gametocytaemia and infectiousness to mosquitoes
were independently estimated from clinical trial data. Predicted percentage reductions in
prevalence of infection and incidence of clinical episodes achieved by ACT were highest in the
areas with low initial transmission. A 53% reduction in prevalence of infection was seen if 100%
of current treatment was switched to ACT in the area where baseline slide-prevalence of
parasitaemia was lowest (3.7%), compared to an 11% reduction in the highest-transmission
setting (baseline slide prevalence ¼ 57.1%). Estimated percentage reductions in incidence of
clinical episodes were similar. The absolute size of the public health impact, however, was
greater in the highest-transmission area, with 54 clinical episodes per 100 persons per year
averted compared to five per 100 persons per year in the lowest-transmission area. High
coverage was important. Reducing presumptive treatment through improved diagnosis
substantially reduced the number of treatment courses required per clinical episode averted in
the lower-transmission settings although there was some loss of overall impact on
transmission. An efficacious antimalarial regimen with no specific gametocytocidal properties
but a long prophylactic time was estimated to be more effective at reducing transmission than
a short-acting ACT in the highest-transmission setting.
Conclusions
Our results suggest that ACTs have the potential for transmission reductions approaching
those achieved by insecticide-treated nets in lower-transmission settings. ACT partner drugs
and nonartemisinin regimens with longer prophylactic times could result in a larger impact in
higher-transmission settings, although their long term benefit must be evaluated in relation to
the risk of development of parasite resistance.
The Editors’ Summary of this article follows the references.
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Since 2000, artemisinin combination therapies (ACTs) have
become widely adopted as ﬁrst-line treatment policy for
uncomplicated P. falciparum malaria in many endemic
countries in response to parasite resistance that rendered
previous ﬁrst line treatments ineffective [1,2]. A secondary
factor in the policy choice of ACT has been the proven ability
of the artemisinin component to reduce patient gametocy-
taemia and infectiousness more than previous ﬁrst-line
treatments [3–6], which shows potential to translate into a
reduction in overall transmission intensity as use of ACT is
scaled up [7]. With the renewed interest in minimising
transmission and moving toward malaria elimination [8], it is
increasingly important to evaluate the ability of antimalarial
treatments not only to cure disease, but also to reduce
transmission. Understanding how pharmacological proper-
ties of ACT and other antimalarials affect transmission, as
well as choice of delivery strategies, can help to maximise the
impact of available resources.
Evidence for transmission or disease reductions following
ACT deployment initially came from studies in South East
Asia [9–12] and Southern Africa [13] which recorded a
reduction in population P. falciparum prevalence or disease
incidence after ACT became the main treatment for clinical
malaria in the area. Since then, data from a number of
settings including Zanzibar [14] and Rwanda have demon-
strated a signiﬁcant reduction in malaria cases following ACT
introduction. While these studies are consistent in suggesting
a beneﬁt of ACT, they had observational, time-trend designs
without control groups, and it is unclear how much of the
effect in these settings was attributable to ACT and how much
to other factors including simultaneous introduction of
vector control measures [11,13], changes in climatic con-
ditions [10], and change in diagnostic quality control.
Furthermore, these observations come from relatively low
transmission settings. In higher-transmission settings, the
asymptomatic reservoir of infection may limit the potential
for transmission reduction by treatment of symptomatic
cases, because greater exposure increases immunity and the
chance of an infection remaining asymptomatic [15,16].
A previous mathematical model of symptomatic case
management predicted moderate to substantial impact of
the nonartemisinin-based antimalarials sulfadoxine-pyri-
methamine (SP) and amodiaquine (AQ) on age-prevalence
patterns of infection and rates of severe disease and mortality
under scenarios of 40% or 100% coverage [17]. Rates of
uncomplicated clinical malaria episodes were reduced in low
but not high transmission settings. Understanding to what
extent ACTs with their additional gametocytocidal effects can
reduce transmission in settings where partially effective
treatments are already in place would aid malaria control
agencies who currently must choose how to divide resources
between drug purchases, drug delivery strategies, and other
control interventions. The decision to maximise the coverage
of the ACT class of drugs beyond the formal health care
sector has substantial cost implications given their higher
price [18], but it would be supported if ACT were likely to
have a substantial effect on transmission. Choosing to invest
in improved diagnostic techniques can save on overtreatment
of fever cases with ACT; however, the importance of this
widespread presumptive treatment for keeping transmission
levels down needs to be investigated.
With increasing investment in research, the range of drugs
in development for treatment of malaria is widening and a
greater number are also becoming available in combination
with artemisinins as ACT [19]. The stronger gametocytocidal
activity of artemisinin derivatives compared to previous ﬁrst-
line antimalarials [20] has received the most attention in
relation to potential transmission reductions by treatment
[7]. However, two other main drug properties impact on
transmission: prophylaxis and efﬁcacy at clearing para-
sitaemia. Artemisinin derivatives have a very short prophy-
lactic time in relation to other antimalarials, and although
they remain highly efﬁcacious in most areas of the world due
to lack of parasite resistance, there are nonartemisinin
antimalarial regimens that are of comparable efﬁcacy in
some regions [21]. Knowledge of the relative importance of
these different drug properties in reducing transmission
could help guide policy makers in choosing between ACTs
with different partner drugs, and in the longer term a
replacement ﬁrst-line treatment, in the eventuality of para-
site resistance or prohibitive cost of ACTs.
Here we develop a mathematical model to describe the
impact of ACTs and other antimalarials on P. falciparum
malaria transmission intensity. We use data from a survey
prior to ACT introduction covering six different trans-
mission settings in Tanzania typical of malaria-endemic
Africa, in order to characterise rates of infection, sympto-
matic episodes, and antimalarial use. We then estimate
potential transmission reduction following introduction of
ACT as a ﬁrst-line treatment and examine how the size of the
reduction depends on coverage, use of diagnostic testing, and
how it compares to the impact of alternative drugs with
different pharmacodynamics. In this way we aim to elucidate
potential goals for ACT policy implementation and inform
future choices of ﬁrst-line treatment.
Methods
Data
We use data from a cross-sectional malariometric survey of
5,667 residents of Tanzania undertaken during the rainy
season (March–June) of 2002 prior to the introduction of
ACT in treatment policy or their licensure and wider
availability in the private market. Details of the methodology
and results of this survey are described in detail elsewhere
[22]. For our analysis, villages were grouped by region
(Kilimanjaro or Tanga) and altitude (,600 m, 600-1200 m,
.1200 m) which is a good proxy for transmission intensity
with an estimated entomological inoculation rate ranging
from less than one infectious bite per person per year at high
altitudes, to about 100 infectious bites per person per year at
low altitudes [23]. The data were stratiﬁed by age groups of 0–
4 y, 5–14 y, and 15–45 y. Symptomatic malaria was deﬁned by
fever (37.58C or above) and parasite density over age- and
altitude-speciﬁc thresholds calculated previously using the
same data [24] (age ,5 y, altitude ,600 m: 4,000 parasites/ll;
age ,5 y, altitude .600 m: 1,000 parasites/ll; age 5–15 y,
altitude ,600 m: 500 parasites/ll; age 5–15 y, altitude .600
m: 250 parasites/ll; age 15–45 y, all altitudes: 500 parasites/ll).
A summary of these data is presented in Table 1 and in Table
II in Text S1. Use of antimalarials in the last 14 d was self-
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and South Pare), parasite resistance testing to the then ﬁrst-
line antimalarial SP was carried out [25]. We assumed that
triple and double mutations in the P. falciparum dhfr and dhfs
genes, respectively, would cause parasitological failure, i.e.,
parasites would not be fully cleared by SP treatment and the
infection would persist, while the double-mutant dhfr would
be sufﬁcient to reduce the effective prophylactic time of SP
[26]. We also assumed that similar resistance levels were
present in all regions in the survey to all widely used
nonartemisinin antimalarials at the time (Table 2).
Incidence rates of symptomatic malaria were calculated
from the observed prevalence of symptomatic cases by
region, altitude and age as prevalence/duration, using
estimates of duration of symptoms from the literature (Table
2). Parasitaemia is assumed to remain asymptomatically once
symptoms have ceased (see model below). We calculated age-
speciﬁc treatment rates per person-year as the proportion
reporting use of antimalarials / reporting time window (14 d)
3365. The relative infectiousness of different age groups was
based on gametocyte densities (Tables I and II in Text S1).
Mathematical Model
Malaria transmission is modelled in human and mosquito
populations using a deterministic compartmental structure
(Figure 1; Text S1). Humans are age-stratiﬁed and can be in
Table 1. Summary of Data from Pre-ACT Cross-Sectional Surveys in Six Transmission Settings in Tanzania
Transmission
Setting
Region Altitude (m) nP f Slide-Positive (%) Symptomatic Pf
Infections
a (%)
Self-Reported Use
of Antimalarials
in Past 14 Days (%)
Highest Tanga ,600 748 57.1 8.13 10.6
Tanga 600-1200 961 30.1 6.62 6.5
Tanga .1200 1,149 21.4 2.9 2.9
Kilimanjaro ,600 249 18.1 3.61 6.1
Kilimanjaro 600-1200 1,441 10.7 0.35 5.5
Lowest Kilimanjaro .1200 1,119 3.7 0.27 2.4
See also Table II in Text S1
aFever .37.5 8C þ Pf density . age- and altitude-specific threshold calculated in [24].
doi:10.1371/journal.pmed.0050226.t001
Table 2. Key Parameters in the Model with Sources
Parameters Definitions and Units Estimates (Data and Literature) Values
Used in
Model
Transmission cycle
parameters
Mean duration of total infectious period
in untreated humans, d
210 [58,59] 210
Mean duration of patent infection in untreated humans, d 121 non immunes [60] 50
Proportion of the human population in high exposure stratum 0.10–0.15 [31,61] 0.10
% mosquito bites received by the high exposure stratum of
the human population
0.8 [31,61] 0.8
Duration of symptomatic episode of malaria, d 4.2 [62]; 2.6 [63]; 10.7–13.1 [64] 10
Treatment
parameters
Proportion of symptomatic cases treated 0.46–0.60 for ‘‘febrile illness: [65]; 0.78 [66] Maximum 0.8
Proportion of treatments which are ACT — 0–1
Proportion of treated individuals with no parasitological
treatment failure: nonartemisinins
,0.4 (fraction of infections without double-triple
SP-resistant genotype in the study area) [25]
0.5
Proportion of treated individuals with no parasitological
treatment failure: ACT
—1
Duration of gametocytaemia in treated infection,
d: nonartemisinins
SP-AQ 66.6 [unpublished analysis] 66
Duration of gametocytaemia in treated infection, d: ACT SP-AS* 14.9; AL 6.3 [unpublished analysis] 15
Relative infectiousness of individuals treated with ACT compared
to nonartemisinin / untreated
0.68 [40] 0.68
Duration of inhibitory antimalarial blood concentration,
d: nonartemisinins (efficacious)
20 piperaquine [67]; .52 SP, fully
sensitive strain [26]
25
Duration of inhibitory antimalarial blood concentration,
d: nonartemisinins (current with treatment failure)
7 SP N51I, S108N mutant, partially
resistant [26]
7
Duration of inhibitory antimalarial blood concentration,
d: ACT (partner drug)
8.5–12.4 lumefantrine [68] 10
The full list of parameters is given in Table I in Text S1.
*AS, artesunate
doi:10.1371/journal.pmed.0050226.t002
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untreated, I; infectious and treated, T; or protected, P, where
the latter state is included to model prophylaxis from
treatment. Susceptible individuals become infected at a rate
dependent on the density of mosquitoes, the human biting
rate, the prevalence of infection in the mosquito, and the
probability of developing blood stage infection following an
infectious bite. The latent period is divided into two stages;
during the ﬁrst the parasites are liver- and early blood-stage
and are subpatent (i.e., not detectable on a blood slide), and
during the second stage the infection becomes patent. The
infection then develops to the infectious, untreated state I,
which is divided into four stages with infectiousness greatest
in the ﬁrst two stages and lower in subsequent stages to
replicate patterns observed in longitudinal human-to-mos-
quito transmission experiments (Table I in Text S1) [27]. We
assume that untreated infections are patent during the ﬁrst
three stages only [28]. Treated infections are described below.
From the fourth stage of the infectious period, individuals
recover to the susceptible state S. Superinfections (infection
by a new parasite clone in addition to the original infection)
occur independently of the initial infection at the same rate
as in susceptible, uninfected individuals and upon super-
infection individuals return to the ﬁrst stage of the infectious
period, extending the overall duration of parasitaemia. A
proportion of infections and superinfections are sympto-
matic and we assume that symptoms occur at the beginning of
an infection and are followed by a longer period of
asymptomatic parasitaemia (Table 2) [29,30]. The model is
stratiﬁed into three age groups (0–4 y, 5–14 y, and 15þ y) to
correspond with the data. Malaria-attributable deaths are not
explicitly incorporated. We allow for heterogeneity of
exposure by additionally stratifying into two risk groups such
that 10% of individuals receive 80% of bites from mosquitoes
[31]. Immunity is modelled by incorporating age-dependency
in the probability that an infectious bite develops into a
blood stage infection [32], the proportion of infections which
become symptomatic [33,34], the rate that an infection
progresses to the ﬁnal subpatent stage (but not the overall
duration of infection [35]), and infectiousness to mosquitoes
[36,37]. We assume negligible short-term change in immunity
so that these parameters do not vary over time [38]. We also
allow for an increase in exposure to mosquito bites with age
due to increasing body surface area [32]. Susceptible vectors
become infected at a rate dependent on the biting rate and
the infectiousness of humans. They progress through latent
and infectious stages but do not clear infection and die at a
constant rate.
Nonartemisinin treatment with a given rate of parasito-
logical failure representing widely used antimalarials at the
time of the Tanzania survey [25] is introduced after the model
has reached endemic equilibrium in the absence of treatment
(Figure 2). After reaching a second equilibrium in the
presence of the nonartemisinin treatment, which represents
transmission at the time of the survey in a given area, a
proportion of the failing nonartemisinin treatments are
replaced by ACT or another efﬁcacious antimalarial and the
model is allowed to reach a third equilibrium. A constant
proportion of symptomatic individuals are treated. Treat-
ment can reduce transmission in three ways in the model: by
reducing the duration for which treated individuals are
infectious (length of time gametocytes remain in the blood-
stream), reducing their infectiousness (density and infectivity
of gametocytes), and providing prophylaxis. The efﬁcacy of
an antimalarial also determines its impact on transmission. In
our model, the infectious period of those in the treated state
T is divided into four stages as in untreated individuals. The
duration of the infectious period is shorter and the infection
is assumed to become subpatent after the ﬁrst stage. In the
case of gametocytocidal antimalarials, infectiousness is
reduced by a constant proportion throughout the infectious
period relative to untreated individuals. The total duration of
effective prophylaxis is equal to the duration of minimum
inhibitory antimalarial concentrations in the blood minus the
duration of liver stage infection, since current, widely used
antimalarials protect only against blood stage parasites. We
assume 100% protection from infection during this time.
This includes protection from superinfection during the
Figure 1. Overview of Model Structure
The main states and transitions of the transmission cycle and treatment in the human population are shown, including presumptive treatment (dashed
lines). Here one age and exposure group and a single type of antimalarial treatment are represented.
doi:10.1371/journal.pmed.0050226.g001
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Impact of Antimalarials on Transmissioninfectious period, and if prophylactic effects persist after
parasites are cleared (depending on the antimalarial being
used), individuals enter the protected state P before return-
ing to the susceptible state S. Treatment clears infection with
a certain percentage efﬁcacy determined by the prevalence of
infections consisting of parasites susceptible to the drug.
Treated patients with resistant parasites experience para-
sitological treatment failure and enter the ﬁrst stage of the
untreated state I. Clinical failure, i.e. parasitological failure
accompanied by symptoms, is not explicitly incorporated in
the model. In our data from the Tanzania survey, individuals
were asked if they had used antimalarials within the previous
14 d. Clinical failure usually occurs on average around 5 d
after treatment [39], so we assume that re-treatment would
occur relatively quickly after the ﬁrst treatment episode.
Therefore it would have little effect on the period prevalence
measure of antimalarial use within the last 14 d, or the stage
at which infection is treated. However, prevalence of
symptomatic malaria was measured on the day of the survey
only, so we use a relatively high estimate of duration of
symptoms (Table 2) to allow for clinical failure. Individuals in
any state can be presumptively treated for malaria regardless
of parasitaemia, which provides a period of prophylaxis (see
also Model Parameterisation and Validation, below). Infected
individuals receiving presumptive treatment also move to the
treated state. Full details of the model, parameter values, and
justiﬁcation of the model assumptions are given in Text S1.
Model Parameterisation and Validation
The effects of nonartemisinin and ACT antimalarials on
the infectiousness of patients to mosquitoes were estimated
from antimalarial trial data, which measured human-to-
mosquito transmission, taking into account subpatent game-
tocytaemia [3,40]. These data were also used to estimate the
duration of infectiousness under different treatment regi-
mens [unpublished analysis]. Patients were included in the
trial regardless of pretreatment gametocytaemia, and there-
fore these estimates allow for lack of ACT effect on mature
gametocytes [20]. Other parameter estimates were obtained
from the literature. Key parameter values are given in Table 2
and a full list is provided in Table I in Text S1.
Following introduction of failing nonartemisinin treat-
ment into the model, the product of the mosquito density and
age-speciﬁc probability of mosquito-to-human transmission
for each age group was varied so that at the subsequent
second equilibrium the age prevalence of patent infection
ﬁtted the observed values for a given area in the survey data.
The proportion of infections that developed symptoms was
set for each age group so as to reproduce the observed
symptomatic malaria age prevalence for a given area at the
second equilibrium. These parameters, used in ﬁtting
prevalence in the model output at the second equilibrium,
are known to have a wide range of possible values across
different settings and age groups (Table I in Text S1) [32,41],
therefore it was not necessary to set boundary values, and the
model output matched the data exactly.
In the survey, an individual’s infection status at the time of
their reported treatment is unknown. Since presumptive
treatment without testing for parasitaemia is common in the
study area as in most malaria-endemic settings, it is likely that
the reported treatment rate exceeds the rate of treatment of
symptomatic malaria infections. We assumed that a max-
imum of 80% of incident symptomatic infections in each age
group receive treatment (if the reported age-speciﬁc treat-
ment rate in the population is sufﬁciently large; otherwise,
this is calculated to match the prevalence of treatment history
in the population). We assumed conservatively that any
remaining treatment episodes were presumptive and were
equally distributed within each age group regardless of
infection state. The rate of presumptive treatment was
Figure 2. Example Model Run over Time for One Age and Exposure Group in One Survey Setting
Initially this shows introduction of infection and baseline endemic equilibrium in the absence of treatment. Nonartemisinins with treatment failure are
introduced first and the model is allowed to reach a second equilibrium, matching the prevalence of slide-positive malaria, clinical malaria and self-
reported treatment in the Tanzania survey data. ACT or another antimalarial regimen are then introduced, and our main outcomes of interest are the
reductions in prevalence and rate of clinical episodes between the second and third equilibriums.
doi:10.1371/journal.pmed.0050226.g002
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person-year in the population estimated directly from the
data minus the age-speciﬁc rate of treatment of symptomatic
cases (80% of the rate of symptomatic episodes per person-
year estimated from prevalence of symptomatic malaria). We
assumed that after introducing a new antimalarial there was
negligible short-term change in presumptive treatment rates,
but the rate of symptomatic malaria was allowed to change
after introduction of a new treatment. We also explored the
impact of introducing diagnostic testing (microscopy or
antibody-based rapid diagnostic tests) together with ACT by
removing presumptive treatment of those without a patent
infection.
Results
ACT Impact on Transmission
The rates of infection, clinical episodes, and treatment in
each transmission setting estimated from the survey prior to
ACT introduction are shown in Table 3. The model-estimated
impact of delivering ACT at complete coverage is shown in
Figure 3A and Table 4. Replacing 100% of current
antimalarial treatments with ACT without any change to
the rates of antimalarial use in the study area is predicted to
decrease the incidence of clinical episodes by between 21.1%
and 52.5% and the prevalence of slide-positive infection by
11.5%–52.9%. This relative impact was largest in the setting
with the lowest transmission levels pre-ACT (slide-prevalence
¼3.7%), and there was a clear trend for decreasing impact as
the pre-ACT transmission level became higher. This trend
matched the ratio of the antimalarial treatment rate per
person-year to the malaria infection rate per person-year in
the populations, which also tended to decrease as pre-ACT
transmission became higher (Figure 3A; Table 3). However,
the absolute impact in terms of the numbers of clinical
episodes averted was predicted to be highest in high trans-
mission settings. An estimated 54.1 and 81.5 clinical episodes
were prevented per 100 persons per year in the two areas of
highest pre-ACT slide-prevalence compared to 4.9 clinical
episodes per 100 persons per year in Kilimanjaro’s lowest-
prevalence area. In our analysis, reductions in clinical disease
incidence are closely correlated with reductions in infection
incidence, because short-term change in population immun-
ity is assumed to be negligible, and therefore clinical disease
is an indicator of transmission levels.
The time taken to achieve the reduction in infection
incidence becomes longer as pre-ACT transmission intensity
decreases (Table 4). With an instantaneous 100% coverage of
ACT, 50% of the total reduction achieved is predicted to
Table 3. Estimates of Transmission, Disease, and Treatment Rates in Six Transmission Settings in Tanzania Prior to ACT from Survey
Prevalence Data and the Model
Pre-ACT Pf
Slide-Prevalence (%)
Region Altitude
(Meters)
Infection
Incidence/pyr
a
Clinical
Episodes/pyr
a
% Infections
Developing
Symptoms
a
Total
Treatment
Rate/pyr
Ratio Treatment
Rate/Infection Rate
57.1 Tanga ,600 33.2 2.57 7.8 2.1 0.064
30.1 Tanga 600-1200 10.5 2.15 23.8 1.3 0.125
21.4 Tanga .1200 5.7 0.93 21.6 0.6 0.112
18.1 Kilimanjaro ,600 4.9 1.32 49.7 1.1 0.228
10.7 Kilimanjaro 600-1200 1.8 0.12 7.4 1.3 0.760
3.7 Kilimanjaro .1200 0.4 0.09 32.4 0.6 1.527
aPopulation average weighted by age group.
pyr, person-year.
doi:10.1371/journal.pmed.0050226.t003
Figure 3. Model Predictions of ACT Impact on Transmission in Six
Transmission Settings in Tanzania Compared to the Pre-ACT Scenario
with Failing Nonartemisinin Treatment
(A) Relative and absolute reductions in clinical episodes achieved by ACT
if treatment rates remained the same and there was a 100% switch to
ACT. Also shown is the pre-ACT ratio of treatment to infection rate.
(B) Relative reductions in clinical episodes by ACT coverage.
doi:10.1371/journal.pmed.0050226.g003
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Impact of Antimalarials on Transmissionoccur within 1–3 wk in the high-transmission settings, whilst
it is predicted to take 2–3 mo in the lowest-transmission
settings. The rate at which incidence decreases slows with
time (Figure 2). Under scenarios of lower coverage of ACT
where a proportion of individuals seeking treatment con-
tinued to be given the less effective, failing antimalarials used
prior to ACT introduction, transmission reductions are
predicted to decrease linearly with ACT coverage (Figure
3B). A full sensitivity analysis of our results is given in Text S1.
Influence of Improved Diagnosis
The importance of presumptive treatment to overall ACT
impact was explored by modelling a scenario in which
additional testing for the presence of parasites is incorpo-
rated into an ACT treatment programme. Under such a
programme, individuals without detectable infection who
seek treatment are no longer prescribed antimalarials;
however, those with asymptomatic infection who have patent
parasitaemia (for example, those who seek treatment due to
symptoms from another illness) continue to be treated. In the
two lowest-transmission settings in Tanzania, reported rates
of treatment per person-year in the cross-sectional survey
were higher than the estimated rates of clinical episodes
(Table 3), suggesting greater overuse of antimalarials in these
areas. Reducing treatment rates through introducing diag-
nosis reduced ACT impact to some extent in the two lowest
transmission settings only (Figure 4A). In these settings, the
model estimates that a relatively high proportion of
antimalarial treatments are used by individuals without
symptomatic malaria or detectable infection. This use of
treatment reduces transmission less efﬁciently because it does
not target the most infectious individuals, but has a small
effect through cure of subpatent infections and prophylaxis.
Similarly, the number of treatment courses required to
indirectly prevent one clinical episode via transmission
impact was greatly reduced by laboratory diagnosis in the
two lowest-transmission settings only (Figure 4B). Improved
diagnosis can reduce treatment rates and thus ACT impact
further if we assume a lower proportion of treatment is used
by symptomatic cases (Figure VIII in Text S1).
Impact on Transmission of Antimalarials with Different
Pharmacodynamic Properties
In addition to investigating ACT impact on transmission,
and thus the impact of a gametocytocidal drug, we used the
model to examine the importance of the efﬁcacy and
prophylactic effects of antimalarials in reducing transmission
(Figure 5). We consider the impact of individual antimalarials
in order to separate out the effects of these drug properties,
however this is intended to be purely theoretical since use of
any antimalarial alone increases the chance of development
of resistance [42]. Using data on SP, it is assumed that the
nonartemisinin treatments in use in the study area at the time
of the survey had only 50% efﬁcacy and a prophylactic time
of 7 d due to high levels of resistance mutations [25,26]. Our
results suggest that these treatments were having little impact
on transmission with an estimated 0.6%–10.7% lower rate of
clinical episodes compared to a scenario without any
antimalarials (Table 4). As before, the impact was largest in
the lower-transmission settings.
Replacing 100% of the failing treatments with a theoret-
ical, 100% efﬁcacious nongametocytocidal antimalarial with
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Impact of Antimalarials on Transmissiona prophylactic time of 10 d (as assumed for a short-acting
ACT) is estimated to reduce the rate of clinical episodes by
2.5%–12.6% (Figure 5A). Again this impact increased as pre-
ACT transmission decreased. However, using a nongameto-
cytocidal antimalarial that had a longer prophylactic time of
25 d as well as 100% efﬁcacy substantially increased its impact
on transmission (Figure 5). Clinical episodes were reduced by
24.0%–33.7% and, in contrast to the gametocytocidal drugs,
this impact increased as baseline transmission increased. This
relationship was observed despite the lower ratio of treat-
ment rate to infection rate at higher transmission (see Figure
3A). In the setting with highest initial slide-prevalence
(57.1%), the impact of such a drug on clinical episodes was
60% higher than the predicted impact of a drug with the
gametocytocidal effects of ACT and a prophylactic time of 10
d (such as artemether-lumefantrine [AL], the most commonly
used ACT) (Figure 5A; Table 4). An ACT with a long-acting
partner drug (25 d prophylaxis) had the highest impact of all
drug types, reducing rates of clinical episodes by 54.1%–
69.1%, with the impact tending to increase with pre-ACT
transmission levels (Figure 5A).
Gametocytocidal drug action was less effective in reducing
transmission from an initially high than from a low level
because following clearance of gametocytes individuals were
more quickly reinfected. By contrast, prophylactic effects
were more important for reducing new inoculations and
clinical episodes in high- than in low-transmission settings,
because there was a greater chance of receiving an infectious
challenge during the prophylactic period. Prophylactic and,
to some extent, gametocytocidal drugs are predicted to have
less effect on infection prevalence than on the incidence of
clinical episodes in higher-transmission settings (Figure 5B).
A similar pattern is observed with other malaria control
interventions [43] because of the nonlinear relationship
between prevalence and incidence of malaria infection [44].
This relationship arises because the time period between new
parasite inoculations is shorter at higher transmission and
superinfection is more common. Therefore, preventing an
inoculation does not reduce the amount of person-time spent
infected, and therefore prevalence, as much as it would in a
lower-transmission setting.
Sensitivity Analysis
Model results were relatively robust to variations in the
majority of key parameters (full details provided in Text S1),
but we found that ACT impact size would be lower in
populations with high heterogeneity in exposure (Figure V in
Text S1). The size of ACT gametocytocidal effects in treated
individuals as well as prophylactic effects was an important
determinant of transmission reductions (Figure VI in Text
S1). We also conﬁrmed that the trends shown in the results
still existed in a much simpliﬁed version of the model, which
did not use the survey data and ignored presumptive
treatment, treatment failure, age, and immune effects,
assuming a constant proportion of infections treated in all
areas. Gametocytocidal drugs still had most impact in lower-
transmission settings, and the reverse was true for prophy-
lactic drug effects (Figure IV in Text S1).
Discussion
Our model shows the potential for an appreciable impact
of ACT on malaria transmission at current rates of
antimalarial treatment in our study area of Tanzania. The
predicted reductions in prevalence of slide-positive infection
at 100% coverage are between 11.5% and 52.9%, which
compare with 13%–42% achieved by insecticide-treated bed
nets (ITNs) in trial settings [43] and, as such, ACT could form
an important part of a transmission reduction programme.
The estimated reductions in rates of clinical episodes of
21.1%–52.5% with a short-acting ACT are lower than pooled
estimates of ITN impact of 50%–62% [43]. In higher-
transmission settings (.20% baseline slide-prevalence), ACT
is predicted to have its smallest relative impact on trans-
mission as found in a previous model looking at SP-AQ [17],
due to a combination of a lower proportion of infections
being treated and the different dynamics of infection
prevalence (Figure 3A; Figure IV in Text S1). However, in
terms of public health impact, the absolute number of clinical
episodes prevented by introducing ACT in high-transmission
settings was much greater, and the courses of treatment
required per episode indirectly averted was substantially
lower given current treatment rates across settings. Further-
more, the direct beneﬁts of effective clearance of parasites
for infected individuals would be considerable. More wide-
Figure 4. Model-Estimated Impact of Introducing Improved Diagnostic
Procedures
Improved diagnostic methods are introduced prior to antimalarial
prescription together with a 100% switch to ACT in six transmission
settings in Tanzania, compared to no change in current treatment use,
(A) on the percentage of clinical episodes prevented and (B) on the
efficiency of treatment at reducing transmission.
doi:10.1371/journal.pmed.0050226.g004
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Impact of Antimalarials on Transmissionspread use of diagnostic tools prior to treatment is predicted
to increase the efﬁciency of ACT in reducing transmission
per treatment course, especially in lower-transmission set-
tings, although it could result in some reduction in the total
impact, as previously suggested [45]. Depending on how
quickly ACTs are made widely available, signiﬁcant impact
could be seen within a few weeks in higher-transmission
settings but would occur over several months in lower-
transmission settings. Our analysis deliberately represents an
ideal scenario in order to estimate the maximum potential
for ACT impact, whilst in reality the difﬁculties of imperfect
patient adherence and of achieving good coverage in all
health sectors [1,46] would reduce the speed and magnitude
of transmission reductions, potentially substantially, as seen
with ITNs outside trial settings.
Our analysis ﬁnds that gametocytocidal properties of
antimalarials have the most relative impact in lower-trans-
mission settings, while prophylactic effects have more impact
in areas with high transmission. An ACT with the gametocy-
tocidal effects of the artemisinin derivative and the prophy-
lactic effect of a longer-acting partner drug is predicted to
have the greatest impact on transmission across all areas in
the short-term time scale of our model. ACT with long-acting
partner drugs are currently in use in some areas; for example,
artesunate-meﬂoquine is recommended by WHO. The more
recently formulated dihydroartemisinin-piperaquine is also
likely to become used more widely [47]. If used widely in the
longer term in higher-transmission settings, the advantage of
the prophylactic effects of these long-acting ACTs would
need to be weighed against a higher selective pressure for
resistant parasite strains [26,48,49]. Careful resistance sur-
veillance would be important. Our ﬁnding that a long-acting
nongametocytocidal drug regimen could have as much or
more effect on transmission than a short-acting ACT in
higher-transmission areas similarly needs to be considered
bearing resistance development in mind. Such a drug
regimen would need to contain two or more efﬁcacious
antimalarials in combination. Existing nonartemisinin com-
binations include SP-AQ and SP-chloroquine, but their use is
limited due to widespread resistance [47]. However, the
predicted impact of long-acting treatments has implications
for future development of nonartemisinin combinations and
their use as a ﬁrst-line treatment, particularly if cost or
development of artemisinin resistance make ACT a less
attractive option. Developing and deploying drugs with
stronger gametocytocidal activity than artemisinins would
also be highly beneﬁcial for transmission reductions accord-
ing to our results (Figure VI in Text S1). Primaquine may be
one such existing drug, but limited evidence does not show a
consistent advantage over artemisinin derivatives [50,51].
Estimated treatment impact did not vary evenly with
baseline slide-prevalence of infection, particularly in the
medium-transmission settings (Figures 3A, 4A, and 5). This is
likely to be due partly to sampling variation resulting from
the smaller sample size in the area with 18.1% baseline
prevalence (Table 1). The prevalence of symptomatic malaria
and reported use of antimalarials are high in this area relative
to the others given its measured infection prevalence,
resulting in higher estimates of treatment impact. However,
as has been found in other endemic populations [52],
reported use of antimalarials also did not decline evenly
with baseline prevalence in the other areas despite larger
sample sizes. Variation in ACT impact due to treatment-
seeking behaviour of populations is likely to be a real feature
of ACT scale-up. Our results should be seen in terms of short-
term impact only, since we do not take into account changes
in the immunity of populations over time. The necessary data
for our model, such as the incidence of infection and the
proportion of infections developing symptoms, are rarely
measured directly due to the difﬁculties of detecting all
superinfections; therefore, we relied on model estimates from
prevalence data, which gave results that were mostly within
the range of the few data available [33,34]. Varying
parameters and the model assumptions that affected these
estimates caused limited change in the results except in the
case of heterogeneity of exposure (see the sensitivity analysis
Figure 5. Model-Estimated Impact of Introducing Antimalarials with 100% Efficacy and Different Pharmacodynamic Properties
Impact is shown on (A) clinical episodes and (B) slide-prevalence of infection in six transmission settings in Tanzania, compared to the pre-ACT scenario
with failing nonartemisinin treatment assuming a 100% switch to these treatments. Short-acting nongametocytocidal: prophylactic time ¼ 10 d, no
specific gametocytocidal action. Short-acting ACT (as Figure 3A): prophylactic time¼10 d, with the gametocytocidal action of artemisinin. Long-acting
nongametocytocidal: prophylactic time ¼ 25 d, no specific gametocytocidal action. Long-acting ACT: prophylactic time ¼ 25 d, with the
gametocytocidal action of artemisinin.
doi:10.1371/journal.pmed.0050226.g005
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Impact of Antimalarials on Transmissionin Text S1). In the highest-transmission setting the estimated
incidence of infection and clinical episodes in the pre-ACT
setting appear high (Table 3), but may be reasonable given
measured entomological inoculation rates [23], and that the
survey was conducted during the season of highest trans-
mission and thus true annual rates would be lower. Whilst the
prevalence of symptomatic malaria in the survey data
decreased with transmission setting, our estimated propor-
tion of infections developing symptoms did not show a clear
trend of increasing as would be expected due to decreasing
immunity (Table 3). This trend was visible across the four
higher-transmission settings, but not in the two sites with
lowest transmission intensity, probably due to the small
numbers of cases meeting our deﬁnition of symptomatic
malaria in these areas (Table 1 in the main text and Table II
in Text S1). However, we had estimates of treatment intake in
the population, and our results are relatively robust to
whether this treatment occurs in symptomatic or asympto-
matic individuals (Figure VIIa–b in Text S1). They are more
sensitive to the accuracy of our treatment data, which is self-
reported, and thus potentially underestimated [53]. Our data
are limited to individuals under 45 y of age, which in these
settings represents around 87% of the population [54]. By
assuming in our model that individuals over 45 y have the
same infection and immunity status as 15- to 45-y-olds, we
may underestimate overall immunity levels in this age group
to some extent. However, our sensitivity analysis showed that
results were not affected substantially by ignoring age
structure (Figure VIIi–j in Text S1). In generalizing our
results to other settings it should be borne in mind that our
slide-prevalence data represent the peak in annual trans-
mission in these areas, whilst immunity levels in the study
populations reﬂect lower transmission during other times of
the year.
Our model predictions are roughly compatible with some
of the trends from observational studies in areas where ACT
was introduced, although it is uncertain to what extent these
trends were attributable to ACT. In studies where trans-
mission was similar to our lowest transmission setting
(Kilimanjaro, .1,200 m) or lower, around 50% [10,12] to
75% [13] reductions in clinical episodes or prevalence
occurred following ACT introduction, although there were
also changes in vector levels during the same time period. In
an area of Zanzibar with transmission levels similar to those
of our second-lowest transmission setting (Kilimanjaro 600–
1,200 m), little clear change in clinical incidence was seen
during 2004 after the introduction of ACT, during which
time 34,724 doses of artemether-lumefantrine were dispensed
to a population of ;85,000 [14]. We cannot be sure what
coverage of ACT this achieved (i.e. what proportion of all
antimalarials used by the population were ACT), but in our
equivalent setting this would amount to ;30% coverage and
a potential ;16% reduction in clinical episodes (Figure 3B),
which could have been masked by the seasonal trends in
Zanzibar or diminished by imperfect patient adherence. As
well as comparing our results to studies of ACT impact, it is
interesting to compare with previous introduction of long-
acting nonartemisinins, which received less attention in terms
of transmission reductions. For example our model suggests
that when SP was ﬁrst widely introduced as an efﬁcacious
drug to replace failing chloroquine treatment, there could
have been a 20%–30% reduction in clinical episodes in
higher-transmission areas (Table 4) due to its long prophy-
lactic time. Documented decreases of .40% in clinical
episodes or hospital admissions have coincided with SP
introduction in areas of intense transmission in southern
Tanzania [55] and on the coast of Kenya [45,56], although as
with ACT these studies were observational and took place in
the context of increasing vector control. Cluster-randomized
trials measuring the transmission impact of different anti-
malarials used as ﬁrst line treatment would be valuable in
order to conﬁrm observational evidence and the ﬁndings of
our model.
With the current interest in reducing malaria transmission
with a view to elimination of the parasite [57], our results
suggest that ACT can be a valuable tool as part of a larger
programme of control interventions, particularly in lower-
transmission settings. We demonstrate that the choice of
appropriate ACT partner drugs or alternative ﬁrst-line
treatments for a given transmission setting could play an
important role in transmission control. Antimalarial proper-
ties therefore need to be taken into account in future drug
development and at a national and international level in
determining treatment policies if substantial reductions are
to be achieved in transmission and morbidity from malaria
across endemic countries.
Supporting Information
Text S1. Extended Methods and Sensitivity Analysis
Found at doi:10.1371/journal.pmed.0050226.sd001 (866 KB DOC).
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Editors’ Summary
Background. Plasmodium falciparum, a mosquito-borne parasite that
causes malaria, kills nearly one million people every year. When an
infected mosquito bites a person, it injects a life stage of the parasite
called sporozoites, which invade human liver cells where they initially
develop. The liver cells then release merozoites (another life stage of the
parasite). These invade red blood cells where they multiply before
bursting out and infecting more red blood cells, which can cause fever
and damage vital organs. Some merozoites develop into gametocytes,
which infect mosquitos when they take a blood meal. In the mosquito,
the gametocytes give rise to sporozoites, thus completing the parasite’s
life cycle. Because malaria parasites are now resistant to many
antimalarial drugs, the preferred first-line treatment for P. falciparum
malaria in most countries is artemisinin combination therapy (ACT).
Artemisinin derivatives are fast-acting antimalarial agents that, unlike
previous first-line treatments, reduce the number of gametocytes in
patients’ blood, making them less infectious to mosquitos, and therefore
have more potential to reduce malaria transmission. These compounds
are used in combination with another antimalarial drug to reduce the
chances of P. falciparum becoming resistant to either drug.
Why Was This Study Done? Because malaria poses such a large global
public-health burden, there is considerable national and international
interest in eliminating it or at least minimizing its transmission. Malaria
control agencies need to know how to choose between available types
of ACT as well as other antimalarials so as to not only cure malaria illness
but also prevent transmission as much as possible. The financial
resources available to control malaria are limited, so for planning
integrated transmission reduction programs it is important for policy
makers to know what contribution their treatment policy could make in
addition to other control strategies (for example, the provision of
insecticide-treated bed nets to reduce mosquito bites) to reducing
transmission. Furthermore, in areas with high levels of malaria, it is
uncertain to what extent treatment can reduce transmission since many
infected people are immune and do not suffer symptoms or seek health
care, but continue to transmit to others. In this study, the researchers
develop a mathematical model to predict the impact on malaria
transmission of the introduction of ACT and alternative first-line
treatments for malaria in six regions of Tanzania with different levels
of malaria transmission.
What Did the Researchers Do and Find? The researchers developed a
‘‘deterministic compartmental’’ model of malaria transmission in human
and mosquito populations and included numerous variables likely to
affect malaria transmission (variables were based on data collected in
Tanzania just before the introduction of ACT). They then used the model
to estimate the impact on malaria transmission of introducing ACT or
other antimalarial drugs with different properties. The model predicted
that the percentage reduction in the prevalence of infection (the fraction
of the population with malaria) and the incidence of infection (the
number of new cases in the population per year) associated with a 100%
switch to ACT would be greater in areas with low initial transmission
rates than in areas with high transmission rates. For example, in the area
with the lowest initial transmission rates, the model predicted that the
prevalence of infection would drop by 53%, but in the area with the
highest initial transmission rate, the drop would be only 11%. However,
because more people get malaria in high-transmission areas, the total
number of malaria illness episodes prevented would be ten times higher
in the area with highest transmission than in the area with lowest
transmission. The model also predicted that, in areas with high
transmission, long-acting treatments which protect patients from
reinfection would reduce transmission more effectively than some
common currently used ACT regimens which are gametocyte-killing but
short-acting. Treatments which were both long-acting and gametocyte-
killing were predicted to have the biggest impact across all settings.
What Do These Findings Mean? As with all mathematical models, the
accuracy of the predictions made by this model depend on the many
assumptions incorporated into the model. In addition, because data from
Tanzania were fed into the model, its predictions are to some extent
specific to the area. Nevertheless the Tanzanian setting is typical of sub-
Saharan malaria-affected areas, and the authors show that varying their
assumptions and the data fed into the model within realistic ranges in
most cases does not substantially change their overall conclusions. The
findings in this study suggest that in low-transmission areas, provided
ACT is widely used, ACT may reduce malaria transmission as effectively as
the widespread use of insecticide-treated bed nets. The findings also
suggest that the use of longer-acting regimens with or without
artemisinin components might be a good way to reduce transmission
in high-transmission areas, provided the development of parasite
resistance can be avoided. More generally, these findings suggest that
public-health officials need to take the properties of antimalarial drugs
into account together with the levels of transmission in the area when
designing policies in order to achieve the highest impact on malaria
transmission.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050226.
  This study is further discussed in a PLoS Medicine Perspective by Maciej
Boni and colleagues
  The MedlinePlus encyclopedia contains a page on malaria (in English
and Spanish)
  Information is available from the World Health Organization on malaria
(in several languages)
  The US Centers for Disease Control and Prevention provides
information on malaria (in English and Spanish)
  Information is available from the Roll Back Malaria Partnership on its
approach to the global control of malaria, on artemisinin-based
combination therapies, and on malaria in Tanzania
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